Categories

Business Ideas
Business Opportunities
Corporate
Home Business
International Business
Management
Online Business
Public Company
Public Relations
Small Business

Popular Articles

Rolls-Royce scouts for second partner
Rolls-Royce is looking to add a second engineering and design services firm in India to cater to its design requirements. Under the government’s $10-billion defence programme, Rolls-Royce has a commitment to offset 50 per cent of its research and development requirements to Indian design companies.

Sunil Jain: Tax Advantage
Most know private sector firms are a lot more efficient than public sector ones, but a little bit of perspective is required here. According to data from the latest budget documents, public sector firms, on average, pay around a fifth more effective tax rates in comparison to their private sector counterparts. So, while public sector companies paid an effective tax rate of 25.69 per cent in 2007-08, the figure was a lower 21.28 per cent for private sector firms. The average of 22.24 per cent for all firms, of course, was much lower than the statutory 33.99 per cent. The reason for this is the tax benefits claimed, obviously more by the private sector, particularly for export profits under the Software Technology Parks of India (STPI) scheme (Rs 11,734 crore) and accelerated depreciation (Rs 14,344 crore of taxes were foregone on this account).

News of the day

Indian aviation needs to focus on basics to take off
After being in trouble for more than a year and losing Rs 10,000 crore, the Indian aviation industry is looking up.
Public Company

Lupin settles litigation with Forest Labs for Alzheimer drug

Drug firm Lupin today said it has settled all litigations relating to memantine tablets, the generic version of US-based Forest Laboratories" Alzheimer drug "Namenda". - Lupin gains on $100 mn FCCB issue - Sunny re-rating of pharma companies - Medicis takes Lupin to US court on patent charge - Lupin gains on Q2 net rise - Lupin: Steady growth">Lupin: Steady growth - Lupin Q2 net up 39% at Rs 160 cr "As per the terms of the settlement, Lupin will be licensed under the relevant patents and would be free to commercially launch its generic product in January 2015, or earlier in certain circumstances," Lupin said in a statement without disclosing the details of the agreement. Lupin had earlier filed an abbreviated new drug application (ANDA) with the US health regulator Food and Drug Administration (FDA) for the generic version of Forest Laboratories" Alzheimer drug "Namenda". The application was filed under the Paragraph IV certification contesting that the patent was invalid or had not been infringed, which if accepted would give a 180 exclusivity period to the Indian firm for marketing the drug in the US, and the move result in the subsequent litigation with Forest Labs. Forest Lab"s "Namenda" tablets had reported a sale of around 1 billion dollars in the US and accounted for 26 per cent of the US-based company’s net revenue last year. "The settlement with Forest is in line with us prudently managing our litigation pipeline and creating value for the company," Lupin Group President Nilesh Gupta said. The shares of the company closed 3.49 per cent lower at at Rs 1,446.70 on the Bombay Stock Exchanges.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009